|
|
Electrocore Inc (NASDAQ: ECOR) |
|
Price: $9.4900
$-0.14 
-1.403%
|
| Day's High:
| $9.869999885559082
| Week Perf:
| 0.21 %
|
| Day's Low: |
$ 9.23 |
30 Day Perf: |
55.96 % |
| Volume (M): |
96,282 |
52 Wk High: |
$ 10.95 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$6.44 |
| Open: |
$9.51 |
52 Wk Low: |
$4.41 |
|
|
| Market Capitalization (Millions $) |
85 |
| Shares
Outstanding (Millions) |
9 |
| Employees |
83 |
| Revenues (TTM) (Millions $) |
34 |
| Net Income (TTM) (Millions $) |
-15 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Electrocore Inc is a medical technology company that focuses on designing and developing non-invasive vagus nerve stimulation therapies for various medical conditions. The company's therapies involve the use of a handheld device that delivers mild electrical stimulation to the vagus nerve through the skin. This stimulation is believed to have a positive impact on conditions such as migraines, cluster headaches, and treatment-resistant depression. Electrocore Inc aims to provide innovative and effective solutions to improve patient outcomes and quality of life.
Company Address: 200 Forge Way Rockaway 7866 NJ
Company Phone Number: 290-0097 Stock Exchange / Ticker: NASDAQ ECOR
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Mon, Sep 22 2025 12:35 PM UTC
In a world where the hustle and bustle of modern life can often lead to increased stress and sleep-related issues, innovative solutions are continuously emerging to enhance well-being. One such solution has recently received notable acclaim. On September 22, 2025, electroCore, Inc. (Nasdaq: ECOR), a pioneering company in bioelectronic medicine and wellness, announced that it...
|
| Product Service News
Published Thu, May 1 2025 1:16 PM UTC
ROCKAWAY, N.J. In a significant development for the intersection of bioelectronic medicine and digital health, electroCore, Inc. (Nasdaq: ECOR), a company recognized for its innovative approaches to wellness, announced on May 1, 2025, that its flagship product, Truvaga Plus, is now compatible with the Apple Health app.Truvaga Plus, a bioelectronic wellness device, is desig...
|
| Management Announcement
Published Wed, Feb 19 2025 1:00 PM UTC
As the trend towards direct-to-consumer medical devices gains momentum, Electrocore Inc. has positioned itself at the forefront of this burgeoning market. The company s vagus nerve stimulator, Truvaga, is now available for purchase on Amazon, the world s largest retail platform, marking a significant step in expanding consumer access to neurostimulation technology. The launc...
|
| Merger and Acquisition
Published Tue, Dec 17 2024 9:05 PM UTC
ElectroCore s Strategic Move: Strengthening Its Bioelectronic Wellness Portfolio Through the Quell PlatformIn a groundbreaking announcement made on November 8, 2024, ElectroCore has confirmed the strategic induction of a new Vice President, alongside the acquisition of NeuroMetrix’s innovative Quell platform. This decisive move not only amplifies ElectroCore’s reach in ...
|
| Shares
Published Fri, Nov 8 2024 9:01 PM UTC
As of November 8, 2024, ElectroCore, Inc. a leading player in the bioelectronic medicine and wellness sector, is positioning itself for future growth by announcing a significant addition to its leadership team. The publicly traded company, listed under the NASDAQ ticker ECOR, will welcome Thomas Freeburg as its new Vice President and Corporate Controller, effective November ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-1.79 $ |
| Revenues (TTM) |
3.85 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.99 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
415,157 |
| Net
Income per Employee (TTM) |
-185,325 |
| Receivable Turnover Ratio (TTM) |
32.9 |
| Inventory Turnover Ratio (TTM) |
2.57 |
| Asset Turnover Ratio (TTM) |
1.96 |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.79 $
|
| Revenues (TTM) |
3.85 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.99 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States Rx |
|
 79.25 % |
of total Revenue |
| General Wellness |
|
16.96 % |
of total Revenue |
| Outside The United States |
|
5.36 % |
of total Revenue |
| T A C S T I M |
|
0.45 % |
of total Revenue |
| In License Or Other |
|
0.33 % |
of total Revenue |
| Product UNITED STATES |
|
96.81 % |
of total Revenue |
| Product UNITED KINGDOM |
|
4.98 % |
of total Revenue |
| Product Other Countries |
|
0.38 % |
of total Revenue |
| License JAPAN |
|
0.18 % |
of total Revenue |
| Bioelectronic Innovations Segment |
|
102.35 % |
of total Revenue |
|
|
2.47%